ClinVar Miner

Submissions for variant NM_000245.4(MET):c.253A>G (p.Lys85Glu)

dbSNP: rs1791469321
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001912564 SCV002170323 uncertain significance Renal cell carcinoma 2022-12-01 criteria provided, single submitter clinical testing This variant is not present in population databases (gnomAD no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MET protein function. ClinVar contains an entry for this variant (Variation ID: 1397620). This variant has not been reported in the literature in individuals affected with MET-related conditions. This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 85 of the MET protein (p.Lys85Glu).
Mendelics RCV002246582 SCV002518235 uncertain significance not specified 2022-05-04 criteria provided, single submitter clinical testing
Ambry Genetics RCV002458753 SCV002739329 uncertain significance Hereditary cancer-predisposing syndrome 2022-01-12 criteria provided, single submitter clinical testing The p.K85E variant (also known as c.253A>G), located in coding exon 1 of the MET gene, results from an A to G substitution at nucleotide position 253. The lysine at codon 85 is replaced by glutamic acid, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Revvity Omics, Revvity RCV003134207 SCV003808790 uncertain significance not provided 2019-10-16 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.